Gregory Sawyer, Ph.D., and colleagues received a Top Poster award at the 2019 Society of Neuro-Oncology conference for their presentation titled “In situ microscopy of drug and immune interactions against biofabricated tumor models.”

Adam Grippin’s cover image for his manuscript titled “Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging” has been selected as a supplementary cover for ACS Nano.

Yonghan He, M.D., Ph.D., has been selected to receive an ASH Abstract Achievement Award for his abstract titled “DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia.”

Julie Johnson, Pharm.D., dean and distinguished professor, was chosen for the 2019 American  College of Clinical Pharmacology Distinguished Investigator Award. The honor recognizes superior scientific expertise and accomplishments by a senior investigator in a distinct area of research in basic or clinical pharmacology. Johnson’s research focuses on cardiovascular pharmacogenomics and genomic medicine implementation.

Larisa Cavallari, Pharm.D., BCPS, FCCP, an associate professor of pharmacotherapy and translational research, has been elected to a three-year term on the American College of Clinical Pharmacy Board of Regents. The 11-member board is responsible for setting policies and establishing procedures for ACCP and developing the strategic plan. Cavallari has been a member of ACCP since 1997 and served as a trustee and chair of ACCP’s Research Institute from 2013-16.

Robert Amdur, M.D., was recently selected as the new editor in chief of the American Society for Radiation Oncology’s clinical practice journal, Practical Radiation Oncology. Dr. Amdur will begin serving alongside the current EIC this summer before starting his official term in January 2021.

Lusine Yaghjyan, M.D., MPH, Ph.D., received a $1.5 million R01 grant from the National Cancer Institute for her study titled “The role of breast stem cells in breast cancer etiology and risk prediction.” This is Dr. Yaghjyan’s first R01.